Cancer Articles
Researchers have discovered a rare type of immune cell that may predict how likely some patients with skin cancer will respond to immunotherapy treatment.
Researchers at City of Hope have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.
A new cancer vaccine designed to detect and fight cancer cells without traditional cancer treatment is entering Phase III clinical trials.
Imperial College Healthcare NHS Trust has enrolled the first United Kingdom (UK) patients who have received an experimental messenger RNA (mRNA) therapy — a type of immunotherapy treatment called mRNA-4359 — in its Phase I/II clinical trial.
FDA approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with unresectable melanoma or metastatic melanoma that previously has been treated with other therapies.
An international early-phase clinical trial has found a "two-for-one" cancer immunotherapy, tebotelimab, is potentially more effective and at least as safe as standard immunotherapies.
Scientists at the University of California, Davis have identified a protein on the CD95 receptor that can “program” cancer cells to die.
Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells, which play a key role in immune response, that eradicated tumors and prevented their recurrence in mouse models of melanoma.
A new study shows that a personalized messenger RNA (mRNA) cancer vaccine plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk of recurrence or death in people with high-risk advanced melanoma.
The U.S. Food and Drug Administration has approved Roche’s Columvi, an antibody-based therapy chemically known as glofitamab.
Adding an experimental mRNA-based vaccine developed by Moderna and Merck & Co to Keytruda reduced the risk that melanoma would spread by 65 percent over treatment with the immunotherapy drug alone, according to a midstage trial.
Investigators have found that a subset of mutations within the overall tumor mutation burden are less likely to be edited out as cancer evolves.